Replies to post #24998 on RespireRx Pharmaceuticals Inc (RSPI)

[davidal66]

BTW, I would support almost any form of dilution here to raise the cash to complete an ADHD trial with CX1739 this year. One might assume this would be in the cards should CX1739 not work in sleep apnea. At 34 cents, we're 'cooked' in any event stock-price wise, so why not lob a hail mary(sleep apnea and ADHD), rather than end with a whimper.